Attention deficit and hyperactivity disorder (ADHD), a prevalent syndrome in children worldwide, is characterized by impulsivity, inappropriate inattention, and/or hyperactivity. It seriously afflicts cognitive development in childhood, and may lead to chronic under-achievement, academic failure, problematic peer relationships, and low self-esteem. There are at least three challenges for the treatment of ADHD. First, the neurobiological bases of its symptoms are still not clear. Second, the commonly prescribed medications, most showing short-term therapeutic efficacy but with a high risk of serious side-effects, are mainly based on a dopamine mechanism. Third, more novel and effi cient animal models, especially in nonhuman primates, are required to accelerate the development of new medications. In this article, we review research progress in the related fi elds, focusing on our previous studies showing that blockade of prefrontal cortical α 2A -adrenoceptors in monkeys produces almost all the typical behavioral symptoms of ADHD.
Introduction
Attention deficit and hyperactivity disorder (ADHD) is one of the most prevalent childhood neurodevelopmental conditions, affecting 3-5% of grade-school children worldwide [1] . It is characterized by i nappropriate levels of inattention, i mpulsivity, and/or hyperactivity [2] [3] [4] . These symptoms develop in childhood, and can persist into adolescence and adulthood [5] . ADHD seriously affects cognitive development [6] [7] [8] , and, without appropriate treatment, has consequences for the risk of anxiety, substance abuse, and depression in adulthood [ 2, 5, 9] .
T he neurobiological bases o f ADHD symptoms are still not clear [10] . Clarifying them can help better understand the biological vulnerabilities that may underlie ADHD in a specifi c patient and how to modulate the responses to treatment, thereby contributing to better and more effective therapy.
It has been suggested that the symptoms involve a dopaminergic mechanism in the prefrontal cortex (PFC) and striatum [11, 12] . Experimentally decreased dopamine (DA) release in the PFC results in ADHD-like symptoms [13, 14] .
To date, DA dysregulation is thought to be central to the neurobiology of ADHD, and its pharmacological treatment, such as m ethylphenidate (MPH, i.e. Ritalin) [15] [16] [17] , levels the DA c oncentration in the synapse and extrasynaptic space in the PFC as a blocker of the DA transporter. MPH ameliorates inappropriate inattention [18] [19] [20] , decreases impulsivity [21] , and enhances inhibitory control [22] . However, as MPH is a prescription psychostimulant, there are strong concerns over drug dependence, paranoia, schizophrenia, and behavioral sensitization that might be caused by longterm therapy, similar to other stimulants [23] [24] [25] .
Converging evidence indicates that the pathophysiology of ADHD has multiple origins [26] [27] [28] [29] [30] [31] [32] ; for instance, norepinephrine (NE) has long been implicated [33, 34] . In this paper, we review research progress in the relevant fi elds, focusing on the potential relationship between prefrontal α 2A -adrenoceptors and ADHD in nonhuman primates [35] [36] [37] [38] [39] . including poor attention regulation [40] , limited working memory [41] , and inability to inhibit inappropriate motor activity [42] .
Working memory is a fundamental higher-order function, underlies a wide range of executive functional processes [43, 44] , and is primarily controlled by the PFC [45, 46] .
It has been shown that ADHD patients have altered architecture and less activation in the PFC [47] [48] [49] . Persistent working-memory problems are the main cognitive defi cit in ADHD [40, 41, 50, 51] .
Attention brings sensory or mental stimuli to the forefront of awareness [ 40, 52] , and plays a pivotal role in mediating the executive functions of the PFC. During distracted states, the capacity to diminish the awareness of relevant stimuli is compromised. Compared to normal peers, ADHD patients show attention defi cits in detecting invalidlycued targets with slower speed and less accuracy [53, 54] .
Inhibitory control of behavior is one of the most important functions of the PFC [55] ; ablation or lesion of the frontal cortex in monkeys induces locomotor hyperactivity [56] [57] [58] . Perhaps the most fundamental deficit in ADHD is the lack of response inhibition [52] . In laboratory studies of tasks that measure inhibitory control, children with ADHD often perform more poorly than both normal controls and children with other psychiatric disorders [59, 60] .
Schulz et al. reported that response inhibition in adolescents diagnosed with ADHD is primarily mediated by fronto-striatal circuitry [61, 62] .
Prefrontal α 2A -Adrenoceptor Blockade Produces
ADHD Phenotypes
ADHD has been posited to be caused by hypofunctional catecholamine systems [63] in multiple brain regions including the PFC [64] [65] [66] and striatum [67] . Implicated in this are NE projections that originate primarily from neurons in the locus coeruleus and send projections to multiple regions, including the PFC [68] . There are many subtypes of adrenergic receptors in the PFC, including the α 2A subtype.
The α 2A -adrenoceptors are localized at both pre-and postsynaptic NE terminals [69] . However, studies in rodents, monkeys, and humans have shown that lower to moderate levels of NE have a beneficial influence on prefrontal cognitive functions through action at post-synaptic α 2A -adrenoceptors [64, 70] .
ADHD symptoms can be mimicked by blockade of α 2A -adrenoceptors in the PFC. To investigate the role of p refrontal α 2A -adrenoceptors in the inhibitory control of behavior, we trained two monkeys to perform a go/no-go task, and the α 2A -adrenergic antagonist yohimbine was infused bilaterally and chronically into the dorsolateral PFC with mini-osmotic pumps. We found that blockade of the α 2A -adrenoceptors selectively impaired the "no-go" performance of monkeys, leaving the "go" performance intact. In quite a few cases, the monkeys should have kept their hands still and not touch the screen (no-go), but they made a response to the screen [38] . In addition, the monkeys' locomotor activity was monitored before, during and after yohimbine infusion into the dorsolateral PFC. Compared to that before administration, the daily locomotor activity increased dramatically during the 8-day administration of yohimbine;
this gradually returned to normal after the infusion was stopped (Fig. 1B) . I nfusion of saline at the same location did not cause locomotor hyperactivity [39] . This work suggests that the α 2A -adrenoceptors in the d orsolateral PFC are associated with locomotor activity, and the dorsolateral PFC dysfunction of α 2A -adrenergic transmission could be one of the main causes of the impulsive behaviors and hyperactivity in children with ADHD.
Due to the limitations of working on nonhuman primates, we also implemented similar experiments on rats to assess the dose-dependent and age effects of yohimbine at a homological cortical site, the medial PFC. The results showed that yohimbine infused into the medial PFC dose-dependently induced hyperactivity in rats of different ages, and the trends showed that the younger the rats, the more hyperactivity presented at the same dose (unpublished data). All these results showed that dysfunction of the PFC α 2A -adrenoceptors results in the behavioral problems seen in ADHD.
ADHD symptoms can also be induced in humans by reducing the stimulation of α 2A -adrenoceptors. Kopeckova et al. investigated a polymorphism in the promoter region of the gene encoding DA beta-hydroxylase, an enzyme that reduces NE synthesis, and found that the affected children had poor sustained attention, weaker impulse control, and impaired executive function [71] . Genetic alterations in α 2A -adrenoceptors also impair PFC executive function, and lead to conditions seen in ADHD [72] . Thus, prefrontal α 2A -adrenoceptors are required for attention and behaviors in humans too.
Prefrontal α 2A -Adrenoceptor Stimulation Ameliorates Cognitive Dysfunctions in ADHD
Behavioral, pharmacological, and electrophysiological research has shown that stimulation of α 2A -adrenoceptors has a beneficial influence on PFC cognitive functions.
Arnsten et al. found that systemic administration of the α 2A -adrenergic agonist guanfacine improves working memory in monkeys [73] . Steere demonstrated that systemic administration of guanfacine improves visual object discrimination reversal performance in aged rhesus monkeys [74] . Our work showed that both systemic administration and local infusion of guanfacine into the PFC improve visuomotor associative learning [70, 75] . Using an iontophoretic technique, stimulation of α 2A -adrenoceptors in the PFC was found to increase the spiking activity associated with working memory in behaving monkeys [37, 76] .
Neuronal activity in the PFC associated with working memory can be enhanced by α 2A -adrenoceptor stimulation through cAMP-HCN signaling pathways [76, 77] . Our work suggested that under normal physiological conditions, the α 2A -adrenoceptors in pyramidal cells can be activated through Gi-cAMP-HCN signaling [78] . On the other hand,
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under stress, activation of α 2A -adrenoceptors to protect PFC functions might occur via the Gi-cAMP-PKA-CaMKII-AMPAR signaling pathway [76] . Both mechanisms together optimize the synaptic inputs to pyramidal neurons and determine the synaptic outputs for PFC cognitive functions.
Indeed, it has been reported that guanfacine at relatively high doses suppresses evoked excitatory postsynaptic currents, and has no enhanced effect or even suppresses delay-related activity [76] . conform to a theoretical rationale for ADHD, account for the neurobiology, and respond to therapeutic interventions both behaviorally and pharmacologically [79] .
N ew Insights to Develop a Primate Model of ADHD
Currently, animal models of ADHD are genetic and non-genetic [80] . The spontaneously-hypertensive rat (SHR), the most widely used model, is a genetic model [81, 82] .
SHRs exhibit hyperactivity [83, 84] , impulsivity/inattention [82, 85] , and poor learning and memory [86] . They also have disturbances in glutamate, DA, and NE functions, which in parallel demonstrate that ADHD patients have defects in the neuronal circuits required for reward-guided associative learning and memory formation [87] . Clearly, the SHRs are not restricted to males [88] . Hyperactive behavior in SHRs is ameliorated only by high doses of amphetamine or MPH [84] , unlike ADHD patients, whose behavioral defi cits can be improved with low doses of MPH. Importantly, ADHD patients show reduced regional cerebral blood fl ow in the frontal cortex [89] , while SHRs do not [90, 91] .
Our to treat ADHD [92] [93] [94] [95] [96] [97] . The selective inhibitor of the NE transporter atomoxetine (tomoxetine or LY139603) has also been reported to alleviate ADHD symptoms [98] . All these medications have achieved much better therapeutic efficacy with less adverse effects [99] than MPH and amphetamines, although there is controversy regarding the long-term effectiveness [100, 101] . 
